Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06030206 · ClinicalTrials.gov registry record · NA

Lung Transplant READY CF 2: A Multi-site RCT

A NA study of Cystic Fibrosis, sponsored by University of Washington.

Active
Registry status
NA
Development phase
132
Enrollment target
11
Study locations

NCT06030206 is a NA study of Cystic Fibrosis that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 132 participants, below the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (26% lower). The trial reports 11 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06030206, a NA study of Cystic Fibrosis, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
132 participants
Enrollment target
11
Study locations

Study Summary

Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for consideration. Patient preference not to undergo lung transplant may account for 25-40% of decisions to defer referral. Rates of death without transplant are higher for people with CF who are members of marginalized communities, including those with Black race, Hispanic ethnicity, or low socioeconomic status. Increasing awareness of lung transplant among people with CF, and promoting understanding of the risks and benefits of transplant, can potentially reduce the number of people with CF who die without a lung transplant. The CF Foundation (CFF) lung transplant referral guidelines were developed to optimize the timing of referral for lung transplant. These guidelines recommend annual conversations with people with CF once their forced expiratory volume in one second (FEV1) is \<50% predicted. Considering lung transplant as a treatment option before it is medically needed will allow more time to learn about lung transplant and address any barriers to lung transplant that may exist. Investigators are interested in understanding how people with CF use lung transplant educational resources and how one prepares for having discussions and/or making decisions about lung transplant as a treatment option for advanced CF. The purpose of this study is to test whether a research website improves patient preparedness for discussions about lung transplant. Investigators also aim to understand whether there are unique factors that affect people with CF from communities with decreased access to transplant ("communities of concern"). Study involvement will span 6 months and study activities will involve the following: * Four Zoom research sessions (15-30 minutes each) * Survey assessments * Acc

Conditions Studied

Interventions

  • BEHAVIORAL Investigator-designed lung transplant education resource (Research Intervention)
  • BEHAVIORAL Publicly available transplant education resource (Attention-control)

Study Locations (11)

California

  • University of California at Los Angeles (UCLA) - Los Angeles

Colorado

  • National Jewish Health - Denver

Connecticut

  • Yale University - New Haven

Kansas

  • University of Kansas - Kansas City

Maine

  • Maine Health - Portland

Maryland

  • Johns Hopkins University - Baltimore

Minnesota

  • University of Minnesota - Minneapolis

Ohio

  • University of Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2023-09-06
Est. Completion 2027-05-31
Phase NA

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT06030206

The ClinicalTrials.gov registry entry for NCT06030206 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (26% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Investigator-designed lung transplant education resource (Research Intervention) is the first listed.

NCT06030206 reports 11 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06030206 about?

NCT06030206 is a clinical study titled "Lung Transplant READY CF 2: A Multi-site RCT". Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for considerati...

What is the current status of trial NCT06030206?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2023-09-06. Estimated completion is 2027-05-31.

What conditions does trial NCT06030206 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT06030206?

The interventions under investigation include: Investigator-designed lung transplant education resource (Research Intervention) (BEHAVIORAL), Publicly available transplant education resource (Attention-control) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06030206?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06030206 being conducted?

This trial has 11 study locations across California, Colorado, Connecticut, Kansas, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.